Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study

Table 2 Risk of re-operation due to post-surgical bleeding after breast cancer surgery according to SSRI prescription among 14,464 women^#.

	Re-operation/Cohort members	Risk (%)	Crude RR (95%CI)	Adjusted RR* (95%CI)
SSRI Prescription
Never	338/12872	2.6	1.0	1.0
Ever	51/1592	3.2	1.2 (0.91, 1.7)	1.1(0.83, 1.5)
Temporality^ of SSRI prescription
Never	338/12872	2.6	1.0	1.0
Current	14/201	7.0	2.7 (1.6, 4.4)	2.3 (1.4, 3.9)
Former	37/1391	2.7	1.0 (0.72, 1.4)	0.93 (0.66, 1.3)

Risk of re-operation occurring in the first fourteen days after surgery was estimated in never, ever, current and former users.
Current users were defined as women with a prescription of SSRI within 30 days before initial breast cancer surgery.
Former users were defined as women with a prescription of SSRI more than 30 days before initial breast cancer surgery.
^# Women diagnosed in Northern Denmark between 1996 and 2007 with complete prescription coverage since 1999.
^Temporality of current use of SSRI was defined as prescriptions within 30 days prior to admission for surgery.
*Adjusted for age
SSRI = Selective serotonin reuptake inhibitors, RR = risk ratio, CI = 95% confidence interval

ISSN: 1471-2482